Literature DB >> 33761040

An HPLC and UHPLC-HRMS approach to study PSMA-11 instability in aqueous solution.

Antonella Iudicello1,2, Filippo Genovese3, Valentina Di Iorio4, Gianfranco Cicoria5, Stefano Boschi6.   

Abstract

BACKGROUND: The stability of precursors and reagents is of utmost importance for developing a robust radiolabelling method that provides high and constant radiochemical yield and radiochemical purity. While performing the QC of the [68Ga]Ga-PSMA-11 injectable solutions according to Ph. Eur. Monograph that has recently been published, a trend to the instability of the standard PSMA-11, the same used as a precursor for [68Ga]Ga-PSMA-11 radiosynthesis, has been observed. This instability led to the formation of a side product in a time-dependent manner. The formation of this compound, besides making the implementation of the Ph. Eur. analytical method more difficult, negatively influenced the radiochemical yield and the radiochemical purity by increasing gallium-68 in colloidal and ionic forms.
RESULTS: The nature of the side product was investigated by adding chelators, such as EDTA, to PSMA-11 solutions and using the combination of UHPLC-HRMS. The results led to the definition of the side product structure, as natFe-PSMA-11, from the combination of the high-affinity chelator HBED-CC, present in the molecule of PSMA-11, and environmental Fe (III).
CONCLUSIONS: Strategies to reduce the risk of low radiolabeling yields and to increase the stability of the PSMA-11 in an aqueous solution were also discussed.

Entities:  

Keywords:  PSMA-11; Quality control; Radiopharmaceuticals; Reagents instability; Reference solution; [68Ga]Ga-PSMA-11

Year:  2021        PMID: 33761040      PMCID: PMC7990985          DOI: 10.1186/s41181-021-00122-3

Source DB:  PubMed          Journal:  EJNMMI Radiopharm Chem        ISSN: 2365-421X


  11 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  The renaissance of the ⁶⁸Ge/⁶⁸Ga radionuclide generator initiates new developments in ⁶⁸Ga radiopharmaceutical chemistry.

Authors:  Frank Roesch; Patrick J Riss
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

3.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

4.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

Authors:  Matthias Eder; Martin Schäfer; Ulrike Bauder-Wüst; William-Edmund Hull; Carmen Wängler; Walter Mier; Uwe Haberkorn; Michael Eisenhut
Journal:  Bioconjug Chem       Date:  2012-03-13       Impact factor: 4.774

Review 5.  Bifunctional Gallium-68 Chelators: Past, Present, and Future.

Authors:  Philipp Spang; Christian Herrmann; Frank Roesch
Journal:  Semin Nucl Med       Date:  2016-09       Impact factor: 4.446

6.  Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies.

Authors:  Matthias Eder; Björn Wängler; Stefan Knackmuss; Fabrice LeGall; Melvyn Little; Uwe Haberkorn; Walter Mier; Michael Eisenhut
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-29       Impact factor: 9.236

7.  Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.

Authors:  Matthias Eder; Oliver Neels; Miriam Müller; Ulrike Bauder-Wüst; Yvonne Remde; Martin Schäfer; Ute Hennrich; Michael Eisenhut; Ali Afshar-Oromieh; Uwe Haberkorn; Klaus Kopka
Journal:  Pharmaceuticals (Basel)       Date:  2014-06-30

Review 8.  Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68.

Authors:  Ruslan Cusnir; Cinzia Imberti; Robert C Hider; Philip J Blower; Michelle T Ma
Journal:  Int J Mol Sci       Date:  2017-01-08       Impact factor: 5.923

9.  Tuning the properties of tris(hydroxypyridinone) ligands: efficient 68Ga chelators for PET imaging.

Authors:  Cinzia Imberti; Yu-Lin Chen; Calum A Foley; Michelle T Ma; Brett M Paterson; Yifu Wang; Jennifer D Young; Robert C Hider; Philip J Blower
Journal:  Dalton Trans       Date:  2019-03-26       Impact factor: 4.390

10.  EANM guideline on the validation of analytical methods for radiopharmaceuticals.

Authors:  Nic Gillings; Sergio Todde; Martin Behe; Clemens Decristoforo; Philip Elsinga; Valentina Ferrari; Olaug Hjelstuen; Petra Kolenc Peitl; Jacek Koziorowski; Peter Laverman; Thomas L Mindt; Meltem Ocak; Marianne Patt
Journal:  EJNMMI Radiopharm Chem       Date:  2020-02-12
View more
  3 in total

1.  Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery.

Authors:  Else A Aalbersberg; Tammie T Cao; Martine M Geluk-Jonker; Jeroen J M A Hendrikx
Journal:  EJNMMI Radiopharm Chem       Date:  2022-09-27

Review 2.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

3.  Optimization of Precursor Preparation in PSMA-11 Radiolabeling to Obtain a Highly Reproducible Radiochemical Yield.

Authors:  Antonella Iudicello; Stefano Boschi; Pietro Ghedini; Frank Lohr; Stefano Panareo
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.